Concepedia

Christy Osgood

CO

Statistics

Publications

13

Citations

847

H-Index

13

Active since

2016

Affiliations

Center for Drug Evaluation and Research(Current)

United States Food and Drug Administration

Center for Devices and Radiological Health

Helen DeVos Children's Hospital

Vanderbilt University

Christy Osgood is an author at Center for Drug Evaluation and Research specializing in medicine, pharmacology, and oncology.

ORCID

Publications per year

2016–2024

13

Publications

13

FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer

Preeti Narayan, Christy Osgood, Harpreet Singh et al. · Clinical Cancer Research · 2021 · 164 citations · Full text

, , +17

FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

Sakar Wahby, Lola A. Fashoyin‐Aje, Christy Osgood et al. · Clinical Cancer Research · 2020 · 150 citations

, , +17

FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer

Mirat Shah, Christy Osgood, Anup Amatya et al. · Clinical Cancer Research · 2022 · 95 citations · Full text

, , +15

Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor

Christy Osgood, Nichole Maloney, Christopher G. Kidd et al. · Clinical Cancer Research · 2016 · 73 citations · Full text

, , +11

Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective

Youwei Bi, Jun-Qiao Liu, Brian D. Furmanski et al. · Annals of Oncology · 2019 · 61 citations · Full text

, , +17

1–5 of 13